Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 109-115

  Dhumal, Ravindra S ^a   Biradar, Shailesh V ^a   Yamamura, Shigeo ^b   Paradkar, Anant R ^a,c   York, Peter ^c  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b JOSAI INTERNATIONAL UNIVERSITY   (Japan)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Amorphous; Bioavailability; Cefuroxime axetil; Nanoparticles; Sonoprecipitation

Indexed keywords

CEFUROXIME AXETIL; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; NONHUMAN; PARTICLE SIZE; PRECIPITATION; RAT; SPRAY DRYING; SURFACE PROPERTY; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CEFUROXIME; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; FEMALE; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POWDER DIFFRACTION; RATS; RATS, WISTAR; SOLUBILITY; SONICATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 50149098764     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.04.001     Document Type: Article

References (21)

1. McEvoy G.K. Cephalosporins: cefuroxime sodium. Cefuroxime axetil. AHFS Drug Information (2003), American society for Hospital Pharmacists Inc., Bethesda, MD 223-231
2. Finn A., Straugun A., Meyer M., and Chubb J. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm. Drug Dipos. 8 (1987) 519-526
3. H.A. Crisp, J.C. Clayton, Amorphous form of cefuroxime ester, U.S. Patent 4,562,181, 1985.
4. H.A. Crisp, J.C. Clayton, L.G. Elliott, E.M. Wilson, Preparation of a Highly pure substantially amorphous form of cefuroxime axetil, U.S. Patent 4,820,1833, 1989.
5. R.H. Muller, A. Akkar, Drug nanocrystals of poorly soluble drugs, in: J.A. Schwarz, C. Contescu, K. Putyera, (Eds.), Encyclopedia of Nanoscience and Nanotechnology. Marcel Dekker, New York, pp. 627-638.
6. Patravale V.B., Date A.A., and Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56 (2004) 827-840
7. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., and Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 (2004) 135-146
8. Mosharraf M., and Nystrom C. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int. J. Pharm. 122 (1995) 35-47
9. Kesisoglou F., Panmai S., and Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 5916 (2007) 31-44
10. Noyes A., and Whitney W. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19 (1897) 930-934
11. Pathak P., Prasad G.L., Meziani M.J., Joudeh A.A., and Sun Y.P. Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation. Langmuir 23 (2007) 2674-2679
12. Zhang J., Shen Z., Zhong J., Hu T., Chen J., Ma Z., and Yun J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int. J. Pharm. 323 (2006) 153-160
13. Chen J.F., Zhang J.Y., Shen Z.G., Zhong J., and Yun J. Preparation and characterisation of amorphous cefuroxime axetil drug nanoparticles with novel technology: high-gravity antisolvent precipitation. Ind. Eng. Chem. Res. 45 (2006) 8723-8727
14. Luque de Castro M.D., and Priego-Capote F. Ultrasound-assisted crystallization (sonocrystallization). Ultrason. Sonochem. 14 (2007) 717-724
15. Louhi-Kultanen M., Karjalainen M., Rantanen J., Huhtanen M., and Kallas J. Crystallization of glycine with ultrasound. Int. J. Pharm. 320 (2006) 23-29
16. Guo Z., Zhang M., Li H., Wang E., and Kougoulos E. Effect of ultrasound on anti-solvent crystallization process. J. Cryst. Growth 273 (2005) 555-563
17. Li H., Wang J., Bao Y., Guo Z., and Zhang M. Rapid sonocrystallization in the salting-out process. J. Cryst. Growth 247 (2003) 192-198
18. Maheshwari M., Jahagirdar H., and Paradkar A.R. Melt sonocrystallization of ibuprofen: effect on crystal properties. Eur. J. Pharm. Sci. 25 (2005) 41-48
19. Paradkar A.R., Maheshwari M., Kamble R.N., Grimsey I., and York P. Design and evaluation of celecoxib porous particles using melt sonocrystallization. Pharm. Res. 23 (2005) 1395-1400
20. Zhao Y.H., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G., Sherborne B., and Cooper I. Evaluation of intestinal absorption data and correlation with human intestinal absorption. Eur. J. Med. Chem. 38 (2003) 233-243
21. Jun S.W., Kim M.S., Jo G.H., Lee S., Woo J.S., Park J.S., and Hwang S.J. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. J. Pharm. Pharmacol. 57 (2005) 1529-1537